Stockreport

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation Off-the-shelf Pro [Read more]